In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Serono/Pfizer Rebif Co-Promotion: Just Act One?

Executive Summary

Analysts generally expressed the view that Pfizer and Serono will both benefit from their agreement to co-promote the multiple sclerosis drug, Rebif. But some question whether the sales and marketing boost Pfizer will give the specialty drug justifies its $200 million upfront payment, or, for that matter, the estimated 35%-40% commission on sales that Serono will be required to pay Pfizer.
Advertisement

Related Content

Antegren: Shaking Up the MS Market?
Antegren: Shaking Up the MS Market?
Who's Got Game in Antibody Development?
Who's Got Game in Antibody Development?
Serono Expands in MS
Deal Statistics Quarterly, Q3 2002
Deal Statistics Quarterly, Q3 2002
Serono's Dealmaking Roll continues
Pfizer's Balancing Act
Pfizer's Balancing Act

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV001947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel